A recent study confirmed that BIRC5 could act as a reliable prognostic indicator in breast cancer patients (Dai et al., 2020), but the expression, clinical significance, and its impact on the immune microenvironment remain largely unclear in low-grade glioma. This evidence concerns the gene BIRC5 and breast cancer.